DeutschNewstral
Article
jdsupra.com on 2017-06-07 02:15
EMA accepts adalimumab biosimilar applications from Fujifilm Kyowa Kirin and Sandoz, and an infliximab biosimilar application from Sandoz
Related news
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com
- Sandoz Launches Adalimumab Biosimilar in Spainjdsupra.com
- Study Shows that Celltrion’s Infliximab Biosimilar is Comparable to Reference Infliximab and Adalimumabjdsupra.com
- AbbVie and Sandoz Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- Sandoz Announces Approval for Biosimilar Hyrimoz® (adalimumab-adaz)jdsupra.com
- Recent Adalimumab Biosimilar Updatesjdsupra.com
- EC Approves Amgen’s Biosimilar Adalimumabjdsupra.com
- Mylan Partners with Fujifilm Kyowa Kirin Biologicsjdsupra.com
- Biosimilar Updates: Epoetin, Rituximab, Adalimumabjdsupra.com
- FDA Approves Boehringer Ingelheim’s Adalimumab Biosimilarjdsupra.com
- FDA Approves Mylan’s Biosimilar of HUMIRA (Adalimumab)jdsupra.com
- Biosimilar Pipeline Developments: Rituximab, Adalimumab, Eculizumab, Infliximab, Pegfilgrastimjdsupra.com
- Biosimilar Development Updates: Infliximab, Ranibizumab, Etanercept, Filgrastim & Trastuzumabjdsupra.com
- Sandoz’s High Concentration Adalimumab Biosimilar Application Accepted by EMAjdsupra.com
- Samsung Bioepis Receives EU Marketing Authorization for Adalimumab Biosimilarjdsupra.com
- Results of Danish Infliximab Biosimilar Switching Study Publishedjdsupra.com
- FDA Approves Sandoz Biosimilar for Tysabri®jdsupra.com
- Sandoz' NEUPOGEN® Biosimilar Now on the Marketjdsupra.com
- Amgen Receives Positive CHMP Opinion for its Biosimilar Adalimumabjdsupra.com
- Sandoz Files Petitions for IPR on Two Abbvie Adalimumab Patentsjdsupra.com